SymBio Pharmaceuticals

Ownership
-
Employees
107
Market Cap
-
Website
Introduction

SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in manufacturing and commercializing drugs for oncology, hematology, and pain management.

Clinical Trials
Related News

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

First Posted Date
2022-08-23
Last Posted Date
2024-12-04
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
1
Registration Number
NCT05511779
Locations
🇯🇵

Research Site, Tokyo, Japan

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

Phase 2
Recruiting
Conditions
Adenovirus Infections
Cytomegalovirus Infection
Interventions
Drug: BCV
First Posted Date
2021-01-13
Last Posted Date
2024-06-21
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
52
Registration Number
NCT04706923
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 2 locations

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Phase 1
Completed
Conditions
Drug Drug Interaction
Interventions
Drug: SyB V-1901
Drug: Cyclosporine
First Posted Date
2020-09-09
Last Posted Date
2021-04-27
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
13
Registration Number
NCT04542252
Locations
🇯🇵

Research Site, Hachioji-shi, Tokyo, Japan

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

First Posted Date
2020-04-21
Last Posted Date
2023-04-18
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
25
Registration Number
NCT04354402
Locations
🇯🇵

Research Site, Yamagata, Japan

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Phase 1
Completed
Conditions
Lymphoma, B-cell, Diffuse
Interventions
Drug: SyB L-0501RI
First Posted Date
2019-04-03
Last Posted Date
2023-11-24
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
37
Registration Number
NCT03900377
Locations
🇯🇵

Research Site, Yamagata, Japan

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumor
Interventions
Drug: SyB C-0501
First Posted Date
2018-07-27
Last Posted Date
2021-04-27
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
18
Registration Number
NCT03604679
Locations
🇯🇵

Research Site, Osakasayama, Japan

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Interventions
Drug: SyB C-1101
First Posted Date
2018-04-11
Last Posted Date
2022-11-16
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
10
Registration Number
NCT03495167
Locations
🇯🇵

Research Site, Kyoto, Japan

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

First Posted Date
2017-12-14
Last Posted Date
2023-04-18
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
40
Registration Number
NCT03372837
Locations
🇯🇵

Research Site, Yamagata, Japan

Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

Phase 3
Terminated
Conditions
Postoperative Pain
Interventions
Drug: SyB P-1501
Drug: SyB P-1501 placebo
First Posted Date
2016-12-30
Last Posted Date
2022-11-17
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
49
Registration Number
NCT03005899
Locations
🇯🇵

Research Site, Wakayama, Japan

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Phase 1
Withdrawn
Conditions
Myelodysplastic Syndrome
Interventions
Drug: SyB C-1101 and Azacytidine
First Posted Date
2016-05-26
Last Posted Date
2022-11-17
Lead Sponsor
SymBio Pharmaceuticals
Registration Number
NCT02783547
Locations
🇯🇵

Research Site, Shinagawa, Tokyo, Japan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy